Re: Twardowski et al.: Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer: A California Cancer Consortium Trial (Urology 2010;76:923-926)

Przemyslaw Twardowski

首页> 外文期刊>Urology >Re: Twardowski et al.: Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer: A California Cancer Consortium Trial (Urology 2010;76:923-926)

【24h】

Re: Twardowski et al.: Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer: A California Cancer Consortium Trial (Urology 2010;76:923-926)

机译：回复：Twardowski等人：患有复发性或转移性尿路上皮癌的患者中的阿柏西普（VEGF-Trap）II期研究：加利福尼亚癌症协会试验（Urology 2010; 76：923-926）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

It recently came to my attention that I have not acknowledged the key contributor to the manuscript "Phase II Study of Aflibercept (VEGF-Trap) in Patients with Recurrent or Metastatic Urothelial Cancer: a California Cancer Consortium Trial."Dr. David Smith from the University of Michigan made a significant contribution to this effort. He was the principal investigator at the University of Michigan and the site accrued 5 of 22 patients to this protocol.

机译：最近引起我注意的是，我尚未认识到手稿“在复发性或转移性尿道上皮癌患者中进行Aflibercept II期研究（VEGF-Trap）：加利福尼亚癌症协会试验”的主要贡献者。来自密歇根大学的David Smith为这项工作做出了重大贡献。他是密歇根大学的首席研究员，该病房在该方案中招募了22名患者中的5名。

著录项

来源
《Urology》 |2012年第5期|共2页
作者
Przemyslaw Twardowski;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献

1. Re: Twardowski et al.: Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer: A California Cancer Consortium Trial (Urology 2010;76:923-926) [J] . Przemyslaw Twardowski Urology . 2012,第5期

机译：回复：Twardowski等人：患有复发性或转移性尿路上皮癌的患者中的阿柏西普（VEGF-Trap）II期研究：加利福尼亚癌症协会试验（Urology 2010; 76：923-926）
2. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. [J] . Twardowski P, Stadler WM, Frankel P, Urology . 2010,第4期

机译：加利福尼亚癌症联合会试验对患有复发性或转移性尿路上皮癌的患者进行阿柏西普（VEGF-Trap）II期研究。
3. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia [J] . MacKayH.J., BuckanovichR.J., HirteH., Gynecologic Oncology: An International Journal . 2012,第1期

机译：II期研究对复发性或转移性妇科癌肉瘤和子宫平滑肌肉肉瘤患者使用aflibercept（VEGF Trap）单药。玛格丽特公主医院，芝加哥和加利福尼亚癌症第二阶段联合体的试验
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. Phase II Study of Aflibercept (VEGF-Trap) in Patients with Recurrent or Metastatic Urothelial Cancer a California Cancer Consortium Trial [O] . Przemyslaw Twardowski, Walter M Stadler, Paul Frankel, -1

机译：阿柏西普复发或转移性泌尿道上皮癌加州癌症财团试验II期临床研究（VEGF-陷阱）患者
7. Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial [O] . Przemyslaw Twardowski, Walter M. Stadler, Paul Frankel, 2010

机译：A-II研究AfliBercept（VEGF-Trap）在复发性或转移性尿路上皮癌患者中，加州癌症联盟患者

Re: Twardowski et al.: Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer: A California Cancer Consortium Trial (Urology 2010;76:923-926)

摘要

著录项

相似文献

相关主题

期刊订阅